In COVID-19 clinical update #91, Dr. Griffin discusses final results of molnupiravir trial, Omicron variant of concern, outcomes in B-cell depleted patients, recovery in T-cell depleted macaques, peptide for induction of T cell immunity, high respiratory viral RNA loads in infants, IgA and T cells transferred to breast milk after vaccination, sensitivity and specificity of ID NOW, post-acute sequelae at 12 months, disease in low and middle income countries.

Hosts: Daniel Griffin and Vincent Racaniello

Subscribe (free): iTunes, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Update on Molnupiravir results (Merck)
• Omicron (Wikipedia)
• P681H and IFN resistance (bioRxiv)
• Synthetic DMARDS and disease severity (Ann Rheum Dis)
• Recovery in T cell depleted macaques (mBio)
• T-cell inducing peptide (Nature)
• Respiratory viral RNA load in infants (J Inf Dis)
• IgA and T cells in breast milk (Cell Rep)
• ID NOW specificity and sensitivity (J Clinical Viral)
• Risk prediction algorithm (Thorax)
• PASC in adults at 12 months (Front Med)
• Letters read on TWiV 837
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]